AT247 – Ultra-Rapid Acting Insulin (URI)

AT247, is an investigational novel meal-time insulin formulation, which aims to significantly accelerate insulin absorption post injection, to enable more effective management of blood glucose levels.  It has been designed to achieve pharmacokinetic and pharmacodynamic properties that more closely match the physiological insulin secretion profile of a healthy individual without diabetes, and hence, significantly improve blood glucose control and enable flexibility of insulin dosing as well as the clinical benefits of inhibiting both hypo and hyperglycaemia.

AT247 is under development as a superior ultra-rapid acting insulin for patients with Type I and Type II diabetics who self-administer insulin via multiple daily injection or continuous infusion (pump therapy) and is compatible with all delivery formats.

AT247 has the potential to be an ideal pump insulin as it has highly favourable pharmacokinetic properties that may facilitate a fully closed loop artificial pancreas; a potentially life changing treatment option, particularly for Type I diabetics.


What is Diabetes?


What is hypoglycaemia and hyperglycemia?

The Medical Need

There is an urgent need for a more rapid acting insulin analogues to deliver improved patient outcomes. By combining both accelerated absorption and faster onset of action of insulin post injection, the following clinical benefits and improved patient healthcare outcomes are possible:

  • Improved post prandial glucose (PPG) control enables the patient to closely manage and control their blood glucose after eating a meal leading to improved long-term outcomes.
  • More Time In Range (TIR) is defined as the % of time spent in the target blood glucose range. More time spent out of range, either too high (hyperglycaemia) or too low (hypoglycaemia) results in long term health complications such as cardiovascular disease, kidney and eye damage. Improving PPG and TIR, particularly around difficult to control meal-times, has the potential to improve long term outcomes and reduce mortality for people living with diabetes.
  • Ultra-rapid acting products allow greater flexibility around the timing of dosing insulin rather than specific time before eating. The combined fast absorption and early onset of action of AT247 may enable greater control and flexibility for patients.
  • Ideal insulin for pump therapy (continuous insulin infusion). Systemic exposure and clearance of current rapid insulins is not fast enough to support closed loop artificial pancreas (AP) delivery systems without risking significant dose stacking and life threating hypoglycaemia. AP systems monitor patient glucose levels continuously by a continuous glucose monitor and from these readings the correct insulin dose is automatically administered to the patient via a wearable insulin pump, at any given time, 24 hours a day. ‘Closing the loop’ remains the panacea for insulin delivery and treatment. There is a critical unmet need for even faster acting insulins such as AT247 to enable a true artificial pancreas. AT247 with its superior pharmacokinetic and pharmacodynamic profile has the potential to enable a fully closed loop artificial pancreas system.

The Market

Diabetes is a large and growing market:

  • Currently there are ~ 463m people with diabetes, with ~56m insulin users and a $22bn global insulin market¹
  • By 2040 there will be an estimated 700m diabetics¹

Whilst there are rapid acting insulins available on the market, there remains a significant need for faster acting insulins as diabetes care advances towards more personalised treatment regimes and sophisticated drug/device combinations such as the automated Artificial Pancreas system.

By developing novel superior formulations of existing therapeutic products, these enhanced therapeutics could deliver significant clinical benefit to patients.

¹International Diabetes Federation, Diabetes Atlas, 2019